Inhibrx Stock Investor Sentiment
| INBX Stock | USD 14.12 0.20 1.40% |
Slightly above 62% of Inhibrx's investor base is looking to short. The analysis of the overall investor sentiment regarding Inhibrx suggests that many traders are alarmed. Inhibrx's investing sentiment can be driven by a variety of factors including economic data, Inhibrx's earnings reports, geopolitical events, and overall market trends.
Inhibrx |
Far too much social signal, news, headlines, and media speculation about Inhibrx that are available to investors today. That information is available publicly through Inhibrx media outlets and privately through word of mouth or via Inhibrx internal channels. However, regardless of the origin, that massive amount of Inhibrx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Inhibrx news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Inhibrx relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Inhibrx's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Inhibrx alpha.
Inhibrx Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Mark Lappe of 9500 shares of Inhibrx at 15.21 subject to Rule 16b-3 | 01/03/2025 |
2 | Inhibrxs SWOT analysis oncology biotech stock faces pivotal year ahead - Investing.com | 01/22/2025 |
3 | Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes 348,000 Position in Inhibrx, Inc. - MarketBeat | 01/30/2025 |
4 | Inhibrx, Inc. Short Interest Down 5.4 percent in January - MarketBeat | 02/20/2025 |
5 | Disposition of 600 shares by Brendan Eckelman of Inhibrx at 24.2007 subject to Rule 16b-3 | 02/27/2025 |
6 | Disposition of 1130 shares by Brendan Eckelman of Inhibrx at 25.8947 subject to Rule 16b-3 | 03/10/2025 |
7 | Disposition of 26667 shares by Brendan Eckelman of Inhibrx at 23.3 subject to Rule 16b-3 | 03/13/2025 |
8 | Inhibrx Biosciences GAAP EPS of -3.09 misses by 0.21, revenue of 100K | 03/17/2025 |
9 | Inhibrx Biosciences Full Year 2024 Earnings Beats Expectations | 03/19/2025 |
10 | Disposition of 19898 shares by Brendan Eckelman of Inhibrx at 33.63 subject to Rule 16b-3 | 03/26/2025 |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.